Early findings from the ongoing phase 1/2 AMPLIFY-7P trial suggest that the investigational vaccine ELI-002 7P could represent a breakthrough in treating pancreatic ductal adenocarcinoma (PDAC), one of the most challenging cancers to treat. The vaccine, designed to target multiple $KRAS$ mutations, has shown a strong and consistent ability to stimulate the immune system in a diverse group of patients.
In a study of 89 patients, 99% experienced measurable activation of KRAS-specific CD4 and CD8 T cells, with immune activity increasing more than 145-fold compared to baseline. These results demonstrate that ELI-002 7P effectively trains the immune system to recognize and attack cancer cells carrying common KRAS mutations.
Importantly, the vaccine produced these responses across a wide variety of human leukocyte antigen (HLA) types, suggesting broad applicability among patients with different genetic backgrounds. This is especially significant for pancreatic cancer, which has historically resisted immunotherapy approaches.
The 7-peptide formulation of ELI-002 is part of a new class of AMP cancer immunotherapies aimed at improving the immune system’s ability to detect and eliminate tumors. The phase 2 portion of the trial is now enrolling 158 patients with resected KRAS-mutant PDAC, comparing the vaccine to standard observation after surger